Toboroz
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441· 2. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433· 3. fázis· Amgen· Forrás
Toboroz
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479· 2. fázis· Upstream Bio Inc.· Forrás
Toboroz
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858878· 3. fázis· Amgen· Forrás
Fut, nem toboroz
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
NCT06604715· 1. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
NCT06660173· 2. fázis· Amgen· Forrás
Toboroz
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06143878· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566· 3. fázis· Amgen· Forrás
Fut, nem toboroz
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Daratumumab
NCT05438043· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
NCT05316155· 1/2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016· 2. fázis· Amgen· Forrás
Fut, nem toboroz
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
NCT04994717· 3. fázis· Amgen· Forrás
Fut, nem toboroz
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004· 2. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
NCT04628494· 3. fázis· Genmab· Forrás
Fut, nem toboroz
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
NCT04521231· 1/2. fázis· Amgen· Forrás
Fut, nem toboroz
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04586426· 1/2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
NCT04181827· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883· 1. fázis· Amgen· Forrás
Fut, nem toboroz
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
NCT03888105· 2. fázis· Regeneron Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
NCT03767244· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
NCT03473743· 1/2. fázis· Janssen Research & Development, LLC· Forrás